Auro-Irbesartan HCT Tablet recall in Canada: NDEA exceeding acceptable limit
In plain language
This recall involves Auro-Irbesartan HCT Tablets sold in Canada. It's being recalled because the affected lot contains NDEA at a level exceeding the acceptable limit. Stop using the product and follow the return steps in the official notice.
What to do
- Stop using the product immediately.
- Check the lot number.
- Return the product as instructed.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
Auro-Irbesartan HCT Tablet
Lot: 1518001-A
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
- 2
Check the lot number
Lot numbers identify specific production batches.
Affected lots: 1518001-A
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
This recall involves Auro-Irbesartan HCT Tablets sold in Canada. It's being recalled because the affected lot contains NDEA at a level exceeding the acceptable limit. Stop using the product and follow the return steps in the official notice.
What should consumers do?
Stop using the product immediately. Check the lot number. Return the product as instructed.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
A potential safety risk has been identified with this product. Stop using it immediately and follow the instructions in the official recall notice.
When was this product recalled?
This product was recalled on April 17, 2019.
Is the Auro-Irbesartan HCT brand affected by this recall?
Yes, Auro-Irbesartan HCT products are affected by this recall. This recall involves Auro-Irbesartan HCT Tablets sold in Canada. It's being recalled because the affected lot contains NDEA at a level exceeding the acceptable limit. Stop using the product and follow the return steps in the official notice.